TSHA
Taysha Gene Therapies Inc
NASDAQ · Biotechnology
$4.61
+0.20 (+4.54%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.12M | 249.41M | 242.81M | 217.48M |
| Net Income | -97,789,215 | 43.60M | 41.01M | 33.31M |
| EPS | — | — | — | — |
| Profit Margin | -1,071.6% | 17.5% | 16.9% | 15.3% |
| Rev Growth | — | +22.8% | -6.9% | +4.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 242.86M | 344.80M | 297.64M | 350.89M |
| Total Equity | 388.52M | 452.11M | 514.03M | 439.34M |
| D/E Ratio | 0.63 | 0.76 | 0.58 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -103,925,009 | 65.17M | 60.77M | 54.08M |
| Free Cash Flow | — | 41.80M | 46.40M | 32.89M |